Literature DB >> 27068937

Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer.

Daniela Achkova1, John Maher2.   

Abstract

Cancer cells employ a variety of mechanisms to evade apoptosis and senescence. Pre-eminent among these is the aberrant co-expression of growth factors and their ligands, forming an autocrine growth loop that promotes tumour formation and progression. One growth loop whose transforming potential has been repeatedly demonstrated is the CSF-1/CSF-1R axis. Expression of CSF-1 and/or CSF-1R has been documented in a number of human malignancies, including breast, prostate and ovarian cancer and classical Hodgkin's lymphoma (cHL). This review summarizes the large body of work undertaken to study the role of this cytokine receptor system in malignant transformation. These studies have attributed a key role to the CSF-1/CSF-1R axis in supporting tumour cell survival, proliferation and enhanced motility. Moreover, increasing evidence implicates paracrine interactions between CSF-1 and its receptor in defining a tumour-permissive and immunosuppressive tumour-associated stroma. Against this background, we briefly consider the prospects for therapeutic targeting of this system in malignant disease.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  c-fms; cancer; clinical prognostic factors; colony-stimulating factor-1; colony-stimulating factor-1 receptor; tumour progression

Mesh:

Substances:

Year:  2016        PMID: 27068937     DOI: 10.1042/BST20150245

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  34 in total

1.  Colony stimulating factor-1 receptor promotes proliferation, migration and invasion in the human nasopharyngeal carcinoma 6-10B cell line via the phosphoinositide 3-kinase/Akt pathway.

Authors:  Jiayu Chen; Yanrong Hao; Jiaxin Chen; Li Huang; Wen Ao; Jiao Yang; Lei Li; Junping Heng; Zhaohon Chen; Wuqing Liang; Xin Hao; Weiwei Gao
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

2.  Comprehensive Analysis of VCAN Expression Profiles and Prognostic Values in HCC.

Authors:  Guangshun Sun; Wubin Zheng; Pengyu Tan; Jin Zhou; Weiwei Tang; Hongyong Cao; Li Liu; Xuesong Shi; Zhouxiao Li; Wenling Zhang
Journal:  Front Genet       Date:  2022-06-24       Impact factor: 4.772

Review 3.  Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance.

Authors:  Astik Priya; Shivani Yadav; Diksha R Borade; Reena Agrawal-Rajput
Journal:  Immunol Res       Date:  2022-10-21       Impact factor: 4.505

Review 4.  Targeting SHP2 phosphatase in hematological malignancies.

Authors:  Rahul Kanumuri; Santhosh Kumar Pasupuleti; Sarah S Burns; Baskar Ramdas; Reuben Kapur
Journal:  Expert Opin Ther Targets       Date:  2022-05-03       Impact factor: 6.797

5.  Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.

Authors:  Sulaiman S Alhudaithi; Rashed M Almuqbil; Hanming Zhang; Elizabeth R Bielski; Wei Du; Fatemah S Sunbul; Paula D Bos; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2020-11-10       Impact factor: 4.939

Review 6.  Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.

Authors:  Xiaohui Wang; Zhiqiang Wu; Wei Qiu; Ping Chen; Xiang Xu; Weidong Han
Journal:  Front Med       Date:  2020-08-13       Impact factor: 4.592

7.  High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers.

Authors:  Muhammad Baghdadi; Hiraku Endo; Atsushi Takano; Kozo Ishikawa; Yosuke Kameda; Haruka Wada; Yohei Miyagi; Tomoyuki Yokose; Hiroyuki Ito; Haruhiko Nakayama; Yataro Daigo; Nao Suzuki; Ken-Ichiro Seino
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

Review 8.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

Authors:  Michael A Cannarile; Martin Weisser; Wolfgang Jacob; Anna-Maria Jegg; Carola H Ries; Dominik Rüttinger
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

9.  Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.

Authors:  Kerstin Strömvall; Elin Thysell; Sofia Halin Bergström; Anders Bergh
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 10.  Cancer immunotherapy: how low-level ionizing radiation can play a key role.

Authors:  Marek K Janiak; Marta Wincenciak; Aneta Cheda; Ewa M Nowosielska; Edward J Calabrese
Journal:  Cancer Immunol Immunother       Date:  2017-03-30       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.